Zhao et al. reports that the activation of STAT3 may be the mechanism for resistance to MEK inhibitor, and the combination of STAT3 and MEK inhibitors can be used as potential therapy for pancreatic and colon cancers with KRAS mutant [7]. Here, MAP2K7 is linked to colonic neoplasm.